Analyst Research and Recommendations: Agios Pharmaceuticals, Inc. (AGIO), HCP, Inc. (HCP)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) tinted gains of +3.96% (+2.14 points) to US$56.19. The volume of 0.85 Million shares climbed down over an trading activity of 515.47 Million shares. EPS ratio determined by looking at last 12 month figures is -6.26. Over the same time span, the stock marked US$99.82 as its best level and the lowest price reached was US$51.62. The corporation has a market cap of US$3.16 Billion.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s earnings per share has been growing at a 3.4 percent rate over the past 5 year when average revenue increase was noted as 11.4 percent. The return on equity ratio or ROE stands at -48.5 percent while most common profitability ratio return on investment (ROI) was -85.4 percent. The company’s institutional ownership is monitored at 98.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 99.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 2.17. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

HCP, Inc. (NYSE:HCP) is worth US$14.2 Billion and has recently risen 3.95% to US$30.23. The latest exchange of 7.4 Million shares is above its average trading activity of 3.27 Million shares. The day began at US$29.09 but the price moved to US$28.82 at one point during the trading and finally capitulating to a session high of US$30.26. The stock tapped a 52-week high of US$29.77 while the mean 12-month price target for the shares is US$28.27.

Currently, the stock carries a price to earnings ratio of 76.34, a price to book ratio of 2.8, and a price to sales ratio of 7.69. For the past 5 years, the company’s revenue has grown -0.3%, while the company’s earnings per share has grown -12.6%. With an institutional ownership near 92.3%, it carries an earnings per share ratio of 0.4.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 15 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.68.